ENTRY       D12186                      Drug
NAME        Vudalimab (USAN)
FORMULA     C5593H8590N1492O1726S34
EXACT_MASS  125360.0765
MOL_WEIGHT  125437.2205
SEQUENCE    (Chain A)
            EIVLTQSPAT LSASPGERVT LTCRASQSVG NDVAWYQQKP GQAPRLLINY ASHRYTGVPD
            RFTGSGYGTE FTLTISSVQS EDFGVYYCQQ DFSSPRTFGG GTKVEIKGKP GSGKPGSGKP
            GSGKPGSEVQ LVESGGGLVK PGGSLRLSCV ASGFTFSNYW MNWVRQAPGK GLEWVAEIRL
            YSNNYATHYA ESVKGRFTIS RDDSKSTLYL QMNNLKTEDT GVYYCTRYYG NYGGYFDVWG
            RGTLVTVSSE PKSSDKTHTC PPCPAPPVAG PSVFLFPPKP KDTLMISRTP EVTCVVVDVK
            HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA
            LPAPIEKTIS KAKGQPREPQ VYTLPPSREQ MTKNQVKLTC LVKGFYPSDI AVEWESNGQP
            ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHSHYT QKSLSLSPGK
            (Chain B)
            EVQLVESGGG LVKPGGSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVSF ISYDGNNKYY
            ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARTG WLGPFDYWGQ GTLVTVSSAS
            TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
            YSLSSVVTVP SSSLGTQTYI CNVNHKPSDT KVDKKVEPKS CDKTHTCPPC PAPPVAGPSV
            FLFPPKPKDT LMISRTPEVT CVVVDVKHED PEVKFNWYVD GVEVHNAKTK PREEEYNSTY
            RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK
            NQVSLTCDVS GFYPSDIAVE WESDGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWEQG
            DVFSCSVLHE ALHSHYTQKS LSLSPGK
            (Chain C)
            EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY GAFSRATGIP
            DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG QGTKVEIKRT VAAPSVFIFP
            PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
            TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
            (Disulfide bridge: A23-A88, A149-A225, A260-B227, A263-B230, A294-A354, A400-A458, B22-B96, B145-B201, B221-C215B261-B321, B367-B425, C23-C89, C135-C195)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
EFFICACY    Antineoplastic, Immunomodulator, Immune checkpoint inhibitor
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Chain A: anti-PDCD1, Chain B: anti-CTLA4
TARGET      PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
            CTLA4 (CD152) [HSA:1493] [KO:K06538]
  PATHWAY   hsa04514(1493+5133)  Cell adhesion molecules
            hsa04660(1493+5133)  T cell receptor signaling pathway
BRITE       Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D12186  Vudalimab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                CTLA4 (CD152)
                 D12186  Vudalimab (USAN)
                PDCD1 (PD1, CD279)
                 D12186  Vudalimab (USAN)
DBLINKS     CAS: 2329669-72-7
///
